{
  "main_header": {
    "sid": 1286501,
    "name": "Bioventus, Inc.",
    "stock_name": "Bioventus, Inc.",
    "full_name": "Bioventus, Inc.",
    "name_url": "stocks-analysis/bioventus-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "7.62",
    "chg": 0.06,
    "chgp": "0.79%",
    "dir": 1,
    "prev_price": "7.56",
    "mcapval": "596.12",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US09075A1088",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "503.18 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bioventus-inc-1286501-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Bioventus, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bioventus-inc-technically-bullish-or-bearish-3547684",
        "imagepath": "",
        "date": "2025-09-20 20:00:42",
        "description": "As of 6 August 2025, the technical trend for Bioventus, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but remains bearish on the monthly. The moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the KST is mildly bullish weekly but mildly bearish monthly, while the OBV and Dow Theory both reflect a mildly bearish stance on the weekly chart.\n\nIn terms of performance, Bioventus has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -31.43% versus the S&P 500's 12.22%, and a one-year return of -38.41% compared to 17.14% for the index...."
      },
      {
        "title": "Is Bioventus, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bioventus-inc-overvalued-or-undervalued-3543982",
        "imagepath": "",
        "date": "2025-09-20 18:34:23",
        "description": "As of 10 May 2022, the valuation grade for Bioventus, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued given its high P/E ratio of 345, a PEG ratio of 3.00, and an EV to EBITDA of 10.75, which are significantly higher than many of its peers. For instance, Axogen, Inc. has a P/E ratio of -146.35 and an EV to EBITDA of 81.74, while ZimVie, Inc. shows a P/E of -80.95 and an EV to EBITDA of 16.76, both indicating a challenging environment for the sector.\n\nIn terms of performance, Bioventus has underperformed compared to the S&P 500, with a year-to-date return of -31.43% versus the index's 12.22%, and a one-year return of -38.41% compared to 17.14% for the S&P 500. This underperformance reinforces the notion that the stock may be overvalued in the current market context...."
      }
    ],
    "total": 6,
    "sid": "1286501",
    "stock_news_url": "https://www.marketsmojo.com/news/bioventus-inc-1286501"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Bioventus, Inc. technically bullish or bearish?

2025-09-20 20:00:42

As of 6 August 2025, the technical trend for Bioventus, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but remains bearish on the monthly. The moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the KST is mildly bullish weekly but mildly bearish monthly, while the OBV and Dow Theory both reflect a mildly bearish stance on the weekly chart. In terms of performance, Bioventus has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -31.43% versus the S&P 500's 12.22%, and a one-year return of -38.41% compared to 17.14% for the index....

Read More

Is Bioventus, Inc. overvalued or undervalued?

2025-09-20 18:34:23

As of 10 May 2022, the valuation grade for Bioventus, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued given its high P/E ratio of 345, a PEG ratio of 3.00, and an EV to EBITDA of 10.75, which are significantly higher than many of its peers. For instance, Axogen, Inc. has a P/E ratio of -146.35 and an EV to EBITDA of 81.74, while ZimVie, Inc. shows a P/E of -80.95 and an EV to EBITDA of 16.76, both indicating a challenging environment for the sector. In terms of performance, Bioventus has underperformed compared to the S&P 500, with a year-to-date return of -31.43% versus the index's 12.22%, and a one-year return of -38.41% compared to 17.14% for the S&P 500. This underperformance reinforces the notion that the stock may be overvalued in the current market context....

Read More

View All News